Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation

Translational Behavioral Medicine

Volumn 1, Issue 1, 2011, Pages 182-190

  Javitz, Harold S ^a   Zbikowski, Susan M ^c   Deprey, Mona ^c   McAfee, Timothy A ^d   McClure, Jennifer B ^b   Richards, Julie ^b   Catz, Sheryl L ^b   Jack, Lisa M ^a   Swan, Gary E ^a  

^a SRI INTERNATIONAL   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c Free and Clear Inc   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Behavioral intervention; Cost effectiveness; Quality adjusted life years saved; Smoking cessation; Varenicline

Indexed keywords

VARENICLINE;

ADULT; AGED; ARTICLE; BEHAVIOR THERAPY; COMBINED PROACTIVE TELEPHONE WEB BASED COUNSELING; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SMOKING CESSATION; TREATMENT DURATION; TREATMENT RESPONSE; WEB BASED COUNSELING;

EID: 84859261514     PISSN: 18696716     EISSN: 16139860     Source Type: Journal    
DOI: 10.1007/s13142-010-0009-8     Document Type: Article

References (57)

1. Fiore, M. C., et al. Treating Tobacco Use and Dependence: 2008 Update, in Clinical Practice Guideline. May 2008, U. S. Department of Health and Human Services. Public Health Service: Clinical Practice Guideline. Rockville, MD.
2. Stead, L. F., Perera, R., & Lancaster, T. (2006). Telephone counselling for smoking cessation. Cochrane Database Of Systematic Reviews, 3, CD002850.
3. Cobb, N. K., et al. (2005). Initial evaluation of a real-world Internet smoking cessation system. Nicotine & Tobacco Research, 7(2), 207-216.
4. Graham, A. L., et al. (2007). Effectiveness of an internet-based worksite smoking cessation intervention at 12 months. Journal of Occupational and Environmental Medicine, 49(8), 821-828.
5. Saul, J. E., et al. (2007). Impact of a statewide Internet-based tobacco cessation intervention. Journal of Medical Internet Research, 9(3), e28.
6. Etter, J. F. (2005). Comparing the efficacy of two Internet-based, computer-tailored smoking cessation programs: a randomized trial. Journal of Medical Internet Research, 7(1), e2.
7. Japuntich, S. J., et al. (2006). Smoking cessation via the internet: a randomized clinical trial of an internet intervention as adjuvant treatment in a smoking cessation intervention. Nicotine Tob Res, 8(Suppl 1), S59-S67.
8. Pike, K. J., et al. (2007). American Cancer Society's QuitLink: randomized trial of Internet assistance. Nicotine & Tobacco Research, 9(3), 415-420.
9. Strecher, V. J., et al. (2008). Web-based smoking-cessation programs: results of a randomized trial. American Journal of Preventive Medicine, 34(5), 373-381.
10. Strecher, V. J., Shiffman, S., & West, R. (2005). Randomized controlled trial of a Web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. Addiction, 100(5), 682-688.
11. Cahill, K., Stead, L. F., & Lancaster, T. (2007). Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, 1, CD006103.
12. Nides, M., et al. (2006). Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Archives of Internal Medicine, 166(15), 1561-1568.
13. Oncken, C., et al. (2006). Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine, 166(15), 1571-1577.
14. Niaura, R., et al. (2008). The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Current Medical Research and Opinion, 24(7), 1931-1941.
15. Gonzales, D., et al. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Journal of the American Medical Association, 296(1), 47-55.
16. Jorenby, D. E., et al. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Journal of the American Medical Association, 296(1), 56-63.
17. Nakamura, M., et al. (2007). Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics, 29(6), 1040-1056.
18. Tsai, S. T., et al. (2007). A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clinical Therapeutics, 29(6), 1027-1039.
19. Tonstad, S., et al. (2006). Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. Journal of the American Medical Association, 296(1), 64-71.
20. Hollis, J. F., et al. (2007). The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. Tobacco Control, 16(Suppl 1), i53-i59.
21. Orleans, C. T., et al. (1991). Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling. Journal of Consulting and Clinical Psychology, 59(3), 439-448.
22. Swan, G. E., et al. (2003). Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Archives of Internal Medicine, 163(19), 2337-2344.
23. Curry, S. J., et al. (1998). Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. The New England Journal of Medicine, 339(10), 673-679.
24. Ringen, K., et al. (2002). Smoking cessation in a blue-collar population: results from an evidence-based pilot program. American Journal of Industrial Medicine, 42(5), 367-377.
25. McClure, J. B., et al. (2009). Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. Journal of General Internal Medicine, 24(5), 563-569.
26. Swan, G. E., et al. (2010). Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine, 38(5), 482-490.
27. Velicer, W. F., et al. (1992). Assessing outcome in smoking cessation studies. Psychological Bulletin, 111(1), 23-41.
28. Patrick, D. L., et al. (1994). The validity of self-reported smoking: a review and meta-analysis. American Journal of Public Health, 84(7), 1086-1093.
29. Gorber, S., et al. (2009). The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine & Tobacco Research, 11(1), 12-24.
30. Swan, G. E., et al. (1993). Cardiovascular reactivity as a predictor of relapse in male and female smokers. Health Psychology, 12(6), 451-458.
31. Garrison, G. D. and S. E. Dugan, Varenicline: a first-line treatment option for smoking cessation. Clin Ther, Mar 2009. 31(3).
32. Fiscella, K., & Franks, P. (1996). Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. Journal of the American Medical Association, 275(16), 1247-1251.
33. Stapleton, J. A., Lowin, A., & Russell, M. A. (1999). Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet, 354(9174), 210-215.
34. Etter, J. F., & Stapleton, J. A. (2006). Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tobacco Control, 15, 280-285.
35. Javitz, H. S., et al. (2004). Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. American Journal of Managed Care, 10(3), 217-226.
36. Wasley, M. A., et al. (1997). The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Preventive Medicine, 26(2), 264-270.
37. Oster, G., et al. (1986). Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. Journal of the American Medical Association, 256(10), 1315-1318.
38. Centers for Disease Control and Prevention, Smoking cessation during previous year among adults-United States, 1990 and 1991. MMWR Morb Mortal Wkly Rep, 1993. 42: p. 504-7.
39. Croghan, I. T., et al. (1997). Cost-effectiveness of treating nicotine dependence: the Mayo clinic experience. Mayo Clinic Proceedings, 72(10), 917-924.
40. Centers for Disease Control and Prevention, Years of healthy life. Stat Notes, 1995. 7: p. 1-14.
41. White, I. R. and J. B. Carlin, Bias and efficiency of multiple imputation compared with complete-case analysis for missing values. Stat Med (Epub ahead of print), 2010.
42. Barnes, S. A., et al. (2010). Missing data assumptions and methods in smoking cessation. Addiction, 105(3), 431-437.
43. Solberg, L. I., et al. (2006). Repeated tobacco-use screening and intervention in clinical practice. American Journal of Preventive Medicine, 31(1), 62-71.
44. Rogers, R. G., & Powell-Griner, E. (1991). Life expectancies of cigarette smokers and nonsmokers in the United States. Social Science & Medicine, 32, 1151-1159.
45. Taylor, D. H., et al. (2002). Benefits of smoking cessation for longevity. American Journal of Public Health, 92, 990-996.
46. Centers for Disease Control and Prevention, Behavorial Risk Factor Surveillance System, in available at: www. cdc. gov/brfss/. Accessed on: June 13, 2005. 2003.
47. Wu, P., et al. (2006). Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health, 6, 300-315.
48. Bolin, K., et al. (2009). Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation-results from four European countries. European Journal of Pub Health, 19(6), 650-654.
49. Knight, H. P., Boler, A., & Baker, C. (2008). Cost-utility analysis of varenciline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics, 26(6), 497-511.
50. Faulkner, M. A. (2009). Smoking cessation: an economic analysis and review of varenicline. Clinico Econ Outcomes Res, 1, 25-34.
51. Leu, R. E., & Schaub, T. (1983). Does smoking increase medical care expenditure? Social Science & Medicine, 17(23), 1907-1914.
52. Tengs, T. O., et al. (1995). Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis, 15(3), 369-390.
53. Cheung, A. M., & Tsevat, J. (1997). Economic evaluations of smoking interventions. Preventive Medicine, 26(2), 271-273.
54. Tsevat, J. (1992). Impact and cost-effectiveness of smoking interventions. American Journal of Medicine, 93(1A), 43S-47S.
55. Weinstein, M. C., & Stason, W. B. (1985). Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annual Review of Public Health, 6, 41-63.
56. Warner, K. E. (1997). Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. PharmacoEconomics, 11(6), 538-549.
57. Mendez, D., Warner, K. E., & Courant, P. N. (1998). Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States. American Journal of Epidemiology, 148, 249-258.